The DOI matches its Crossref record; 211 of the 213 references it cites were found in a registry or an index.
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
Open accessAbstract
The potential therapeutic use of some Cannabis sativa plant compounds has been attracting great interest, especially for managing neuropsychiatric disorders due to the relative lack of efficacy of the current treatments. Numerous studies have been carried out using the main phytocannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD displays an interesting pharmacological profile without the potential for becoming a drug of abuse, unlike THC. In this review, we focused on the anxiolytic, antidepressant, and antipsychotic effects of CBD found in animal and human studies. In rodents, results suggest that the effects of CBD depend on the dose, the strain, the administration time course (acute vs. chronic), and the route of administration. In addition, certain key targets have been related with these CBD pharmacological actions, including cannabinoid receptors (CB1r and CB2r), 5-HT1A receptor and neurogenesis factors. Preliminary clinical trials also support the efficacy of CBD as an anxiolytic, antipsychotic, and antidepressant, and more importantly, a positive risk-benefit profile. These promising results support the development of large-scale studies to further evaluate CBD as a potential new drug for the treatment of these psychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“CBD’s therapeutic potential for reducing depression-like behavior has been shown, since it interacts with a wide range of brain molecules395,396.”
From Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential (2023) · cites this paper as [396]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,389
Psychological autopsy studies of suicide: a systematic review.
CAVANAGH, J. T. O., CARSON, A. J., SHARPE, M., & LAWRIE, S. M. (2003) · Psychological Medicine · doi:10.1017/s0033291702006943 · Cited by 2,207
Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 2,047
Willner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno‐Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,595
Schizophrenia as a Disorder of Neurodevelopment
Lewis, D. A., & Levitt, P. (2002) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.25.112701.142754 · Cited by 1,163
Chronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Research works printed but not linked: 5
- Patel, V., Laxminarayan, R., Medina-Mora, M.L., Dua, T., and Chisholm, D. (2016). Chapter 2 Global burden of mental, neurological and substance use disorder: An analysis from the global burden of disease study 2010. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, The International Bank for Reconstruction and Development. [3rd ed.].
- Hawksworth, G.M.K. (2004). Metabolism and Pharmacokinetics of Cannabinoids, Pharmaceutical Press.
- Sylantyev, S.J.T., Ross, R.A., and Rusakov, D.A. (2011, January 12–16). The enigmatic receptor GPR55 potentiates neurotransmitter release at central synapses. Proceedings of the Neuroscience Meeting Planner Washington, DC: Society for Neuroscience Online: Program, Washington, DC, USA. Program 653.01, Poster B28.
- Heather, A., Church, A.C., and Lucey, J.V. (2012). Core Psychiatry, Elsevier. [3rd ed.].
- Aragones, 2009, Comorbidity of major depression with other common mental disorders in primary care patients, Aten Primaria, 41, 545
Cited by
Sorted by citations
Yuan, M., Yang, B., Rothschild, G., Mann, J. J., Sanford, L. D., Tang, X., Huang, C., Wang, C., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01519-z · Cited by 246
“394 CBD ’ s therapeutic potential for reducing depression-like behavior has been shown, since it interacts with a wide range of brain molecules 395,396 .”
BackgroundCannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain
Stella, B., Baratta, F., Pepa, C. D., Arpicco, S., Gastaldi, D., & Dosio, F. (2021) · Drugs · doi:10.1007/s40265-021-01579-x · Cited by 181
Grifoni, L., Vanti, G., Donato, R., Sacco, C., & Bilia, A. R. (2022) · Molecules · doi:10.3390/molecules27186070 · Cited by 118
Latest updates on the serotonergic system in depression and anxiety
Lin, J., Liu, W., Guan, J., Cui, J.-N., Shi, R.-L., Wang, L., Chen, D., & Liu, Y. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1124112 · Cited by 88
Rahman, M. M., Islam, F., Parvez, A., Azad, A., Ashraf, G. M., Ullah, M. F., & Ahmed, M. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2101042 · Cited by 76
Metadata
- Authors
- García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J.
- Affiliations
- Neurosciences Institute, University Miguel Hernández-CSIC, Avda de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain
- Consejo Superior de Investigaciones Científicas (ES)
- Corresponding author
- Manzanares, Jorge
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2020-11-19
- Volume
- 10
- Issue
- 11
- Pages
- 1575
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC7699613
- OpenAlex
- W3101299715
- Cited by
- 306
- References
- 213
- Citations by year
- 2026: 24 · 2025: 79 · 2024: 62 · 2023: 66 · 2022: 46 · 2021: 29
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- cannabidiol, anxiety, depression, psychosis, anxiolytic effects, antidepressant effects, antipsychotic effects, tetrahydrocannabinol, phytocannabinoids, cannabinoid receptors, CB1 receptor, CB2 receptor, 5-HT1A receptor, neurogenesis, dose-dependent effects, route of administration, clinical trials, risk-benefit profile
- MeSH terms
- Animals, Anxiety, Cannabidiol, Depression, Dose-Response Relationship, Drug, Drug Administration Routes, Humans, Psychotic Disorders, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
